Puma Biotechnology Inc. (NASDAQ:PBYI) went up by 0.74% during the previous trading session, and it is maintaining the win ahead of Monday’s trading session. The share price of the Biotechnology giant went up by $9.55 to trade ended Monday trading at $9.48. This is up from the $9.48 price recorded on Friday’s trading session. Thanks to this latest performance, PBYI is closer to the higher price 52-week target of $16.00 and further from the lowest price target of $6.00. Its performance from the start of the year has also been positive, with PBYI up by 9.14% year-to-date.
Puma Biotechnology Inc. (PBYI) started the day trading at $9.25 and recorded an intraday high of $9.595. It also recorded an intraday low of $9.11 during Monday’s trading session. Puma Biotechnology Inc. is a very active stock that recorded a trading volume that is less than -14.47% of the average daily trading volume on Monday. The stock’s trading volume on Monday was 995904, which is less than -14.47 of the total average daily trading volume of 1.14 million.
Puma Biotechnology Inc. (NASDAQ:PBYI) 2020 Performance Impressive
The increase in PBYI’s stock price on Monday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of PBYI currently stands at $15.00, which is higher than the current trading price of the stock by 36.33%. However, PBYI’s current trading price is -73.64% lower than the 52-week low price of $5.50. In terms of trading volume, Puma Biotechnology Inc. currently experienced healthy participation during the last trading session. 995904 shares of Puma Biotechnology Inc. were traded on the stock exchange on Monday, which is less than -14.47% of the 1.14 million average trading volume of the stock.
The performance of the stock has been positive over the past year. PBYI’s performance over the past one year has seen it plunge by -25.51%, while the stock has gone up by 2.80% in the last six months. The quarterly performance of PBYI currently stands at 50.63%, and it is down by -25.10% in the last month. The only negative figure was from the weekly performance, which currently reads -15.86%. At the time of writing PBYI’s report, the company has a total market cap of $379.04M, making it one of the largest publicly-traded companies in the world.Puma Biotechnology Inc. also has over 269 employees all over the world.
PBYI Insider Activities
For Puma Biotechnology Inc., insiders hold 95.70% of all company shares. The insider transactions over the past six months are up by 5.70%. During that period, insiders bought 259,909 shares in 6 transactions. In that same period, insiders sold 12,524 of their shares in 15 transactions. After these transactions, insiders at Puma Biotechnology Inc. now hold 4.56M shares, which is over 88.81% of the total company stocks. Institutional investors currently hold a large chunk of the PBYI shares, as they control 11.59% of the company’s total stock.
PBYI Fundamental Analysis
For Puma Biotechnology Inc., the stock’s diluted earnings per share (EPS) stands at -2.12. In the coming year, analysts expect the EPS to be -0.52. The stock’s EPS growth this year is 34.90%, 16.20% in the previous five years. In terms of revenue, Puma Biotechnology Inc.’s quarterly sales (YOY) is shrinking at -0.29, which is lower than the average annual revenue of 16.20% over the past half a decade.
The Return on Investment (ROI) on Puma Biotechnology Inc.’s stock currently stands at -56.50%, and it has a net profit margin of -36.70%. The operating margin of the company is -31.80%, and its gross margin is 83.10%.
PBYI Analysts Prediction
In October 08, 2019, several analysts reiterated their positions on the Puma Biotechnology Inc. stock and predicted its performance to their investors. The analysts at Goldman believe PBYI is still a Sell and set the price target between $24 and $8. Another analyst that has a Neutral rating for PBYI is Cantor Fitzgerald, which set a price target of between $57 and $20.
Stifel and Citigroup also believe that Puma Biotechnology Inc.’s stock is outperforming at the moment.
At the moment, Puma Biotechnology Inc.’s Total Debt to Equity ratio stands at 10.19, and they have a long-term Debt to Equity ratio of 10.19.
PBYI Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of PBYI currently stands at -14.44%, while the SMA50 is -7.93%. The biggest one is the SMA200, which is currently reading -0.36% ahead of Monday’s trading session. The Relative Strength Index of this stock is 41.33.